Morimatsu acquires Pharmadule

NewsGuard 100/100 Score

Morimatsu Industry Co., Ltd., the privately owned Japanese pioneer of tank technology, has acquired Pharmadule AB of Sweden, the world leader of modular manufacturing facilities for the pharmaceutical & biopharmaceutical industries. The companies have been working together since the fall of 2009 and signed a collaboration agreement in January, 2010. The two companies' offerings complement each other perfectly and together the two organisations will form a strong combination. The new company will be named Pharmadule Morimatsu AB, and is headquartered in Stockholm, Sweden.

The acquisition is a natural step of a cooperation that started 2 years ago. Through the acquisition Morimatsu gains access to the modular construction technology that Pharmadule has developed and which can be adapted for various industries. Through Morimatsu's presence in China and its extensive experience in process systems, Pharmadule can take advantage of more cost effective manufacturing and supplement Morimatsu's product portfolio of process skids and modules.

Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd. (SMP), a member of the Morimatsu group, has specialized in the fabrication of process skids and modules for the pharmaceutical and biopharmaceutical industries as well as for the cosmetics and food and beverage industries. SMP is working closely together with Pharmadule Morimatsu to create additional value for the customers. "We can now offer not only modular manufacturing buildings but also the process unit operations in the form of process skids and process modules. This is the first time a supplier can offer a truly integrated production service to its clients, all fabricated in the same workshop", says Daniel Ding, CEO of Pharmadule Morimatsu.

Source:

Morimatsu Group

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles